MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 14 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-<i>BRCA</i> homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma
David M. O’Malley, Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin +14 more
2018· article· en· Molecular Cancer Therapeutics· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affno abstractunlabeled
PARP pairs up to PARsylate
Nicolas Coquelle, J. N. Mark Glover
2012· letter· en· Nature Structural & Molecular Biology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare L. Scott, Philipp Harter, Linn Woelber, Jonathan A. Ledermann +18 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
4
citations

How this was built: Screen · Findings · About